NPCE
NEUTRALAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Stock trades at a significant premium to book value, relying entirely on future growth expectations.
- P/S ratio is moderate for the sector
- P/B of 27.07 is excessive
- Negative Forward P/E
- No Graham Number due to lack of earnings
Growth rates are healthy and the company is successfully narrowing its losses.
- Strong YoY revenue growth
- Consistent earnings beats
- Positive EPS trajectory
- Still not profitable
Recent performance is strong, but long-term historical returns are negative.
- Strong 3Y return (+219.8%)
- Recent 6M momentum (+41.9%)
- Poor 5Y performance (-38.5%)
High liquidity is offset by poor fundamental health scores and high leverage.
- High Current Ratio (5.28)
- Piotroski F-Score of 3/9 (Weak)
- High Debt/Equity (3.72)
- Negative ROE (-158.74%)
Company is in a growth phase and does not distribute capital.
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for NPCE and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
NPCE
NeuroPace, Inc.
Primary
|
-38.5% | +219.8% | +43.9% | +41.9% | +8.2% | +5.8% |
|
OFIX
Orthofix Medical Inc.
Peer
|
-70.9% | -30.2% | -4.0% | -14.4% | +8.4% | +5.5% |
|
TRDA
Entrada Therapeutics, Inc.
Peer
|
-43.4% | -5.2% | +70.6% | +117.0% | +19.9% | -2.4% |
|
STRO
Sutro Biopharma, Inc.
Peer
|
-83.1% | -30.0% | +506.7% | +212.4% | +44.8% | +22.0% |
|
PIII
P3 Health Partners Inc.
Peer
|
-99.5% | -95.6% | -74.5% | -72.2% | -4.2% | -5.3% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
NPCE
NeuroPace, Inc.
|
NEUTRAL | $516.79M | - | -158.7% | -21.5% | $15.35 | |
|
OFIX
Orthofix Medical Inc.
|
BEARISH | $516.66M | - | -19.3% | -11.2% | $12.87 | Compare |
|
TRDA
Entrada Therapeutics, Inc.
|
NEUTRAL | $519.14M | - | -39.1% | -% | $13.56 | Compare |
|
STRO
Sutro Biopharma, Inc.
|
BEARISH | $522.7M | - | -% | -186.5% | $31.55 | Compare |
|
PIII
P3 Health Partners Inc.
|
BEARISH | $507.93M | - | -6952.6% | -10.1% | $2.5 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-20 | LACOB JOSEPH S | Director | Stock Award | 865 | $11,245 |
| 2026-03-20 | FISCHER FRANK M | Director | Stock Award | 1,826 | $23,738 |
| 2026-03-20 | GEIGER URI | Director | Stock Award | 913 | $11,869 |
| 2026-03-20 | KUMAR RAKHI | Director | Stock Award | 1,153 | $14,989 |
| 2025-12-19 | LACOB JOSEPH S | Director | Stock Award | 678 | $11,248 |
| 2025-12-19 | FISCHER FRANK M | Director | Stock Award | 1,431 | $23,740 |
| 2025-12-19 | GEIGER URI | Director | Stock Award | 715 | $11,862 |
| 2025-12-19 | KUMAR RAKHI | Director | Stock Award | 904 | $14,997 |
| 2025-12-15 | MORRELL MARTHA J | Officer | Sale | 25,000 | $399,250 |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning NPCE from our newsroom.